SCHEMBL23477857

SCHEMBL23477857

Nc1ncnc2c1ncn2[C@H]1CC[C@@H](CO[P@@](=O)(S)O[C@H]2C[C@H](n3cnc4c(N)ncnc43)O[C@@H]2CO[PH](=O)O)O1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.50
▸ ENPP1 P22413 3/20 0.48
▸ P2RY1 P47900 2/20 0.48
▸ DNPH1 O43598 1/20 0.46
▸ PRKAB2 O43741 1/20 0.46
▸ TRPM2 O94759 1/20 0.46
▸ LDHA P00338 1/20 0.46
▸ ADRB2 P07550 1/20 0.46
▸ FBP1 P09467 1/20 0.46
▸ SRC P12931 1/20 0.46
▸ ADORA1 P30542 1/20 0.46
▸ P2RY2 P41231 1/20 0.46
▸ PRKAG1 P54619 1/20 0.46
▸ PRKAA2 P54646 1/20 0.46
▸ PDE4D Q08499 1/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ PRKAA1 Q13131 1/20 0.46
▸ PDE3A Q14432 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ TAS1R3 Q7RTX0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23477825 0.92 POLB (0.48) POLB
SCHEMBL25964517 0.90 P2RY1 (0.49) POLBP2RY1DNPH1PRKAB2TRPM2
SCHEMBL20763160 0.90 POLB (0.54) POLBENPP1P2RY1DNPH1PRKAB2
SCHEMBL22352121 0.90 POLB (0.54) POLBENPP1P2RY1DNPH1PRKAB2
SCHEMBL18822610 0.88 POLB (0.53) POLBENPP1P2RY1DNPH1PRKAB2
SCHEMBL25967106 0.88 POLB (0.53) POLBENPP1P2RY1DNPH1PRKAB2
SCHEMBL21299334 0.88 POLB (0.50) POLBENPP1P2RY1DNPH1PRKAB2
SCHEMBL22930684 0.87 POLB (0.47) POLBENPP1P2RY1DNPH1PRKAB2
SCHEMBL18823061 0.87 POLB (0.47) POLBENPP1P2RY1DNPH1PRKAB2
SCHEMBL22219988 0.87 POLB (0.40) POLBENPP1P2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170043-A1 DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS CHINOOK THERAPEUTICS, INC. 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170043-A1 DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS STING1, TLR9, TLR3 POLB 3391/4885ENPP1 3112/4885P2RY1 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback